Health Care · Medicinal Chemicals & Botanical Products

BTMD biote Corp. SEC Filings & Insider Trading Activity 2026

company
CIK 181925357 filings
Russell 2000

BTMD at a glance

biote Corp. (BTMD, SEC CIK 1819253) filed its latest 10-K annual report on March 13, 2026, a 10-Q quarterly report on November 9, 2026, an 8-K current report on November 4, 2026 and Form 4 insider filings as recently as August 12, 2026. SignalX summarizes each filing with AI and tracks the company's insider trades and institutional holders.

  • For the fiscal year ended December 31, 2025 (FY2025), biote Corp. (BTMD) reported revenue of $192.2 million (down 2.5% from FY2024) and net income of $27.0 million. Diluted EPS was $0.74.
  • The most recent insider open-market purchase reported on Form 4 was by Beer Marc D on August 11, 2026 of 16,000 shares at $1.55 per share.

Source: SEC EDGAR (XBRL financial data, 13F-HR and Form 4 filings).

Revenue · FY2025
$192.2M
−2.5% vs prior year
Insiders · 90 days
0 buys · 0 sells
No open-market trades
Latest 8-K
Nov 4, 2026
Item 2.02

AI 10-K Annual Report Analysis

Latest 10-K, fiscal year ended Dec 31, 2025

Full analysis →

Business Overview

  • Core business: hormone optimization training and Biote-branded dietary supplements sold to Biote-certified practitioners and partnered clinics
  • Strategic emphasis on managing risks related to outsourcing facilities that compound bioidentical hormones, including recent acquisition of Asteria Health (Mar 2024)
  • Geographic revenue concentration with 53% from TX, OK, NM, CO, AR, LA, MS, AL, GA, FL in FY 2025, highlighting regional regulatory sensitivity
  • Key operational risk: termination notice from AnazaoHealth for Pharmacy Services Agreement, extended through Dec 2027 per 2025 amendment
  • Growth-focused strategy may depress near-term profitability due to increased marketing, acquisitions and infrastructure scaling demands

Risk Factors

  • Regulatory risk from potential liability and recalls linked to compounded drug formulations via outsourcing facilities, posing reputational harm
  • Macroeconomic exposure from 2.5% revenue decline to $192.2M in 2025 due to slowdown in new clinic additions and procedure volumes
  • Operational risk relating to vertical integration of Asteria Health, impacting cost structure with a 19.0% decrease in pellet procedure costs
  • Market disruption from Amazon e-commerce channel growth boosting Biote-branded supplement revenue by $6.9M in 2025 as competitor distribution shifts
  • Legal/financial risk from $4.9M legal settlement expense in 2024 (Carie Boyd case), reduction improved 2025 SG&A expense by 5.2% to $101.8M

AI summary of the BTMD 10-K filed . Generated from the filing text; verify against the original.View on SEC EDGARHow to read a 10-K

AI 10-Q Quarterly Report Analysis

Latest 10-Q, quarter ended Sep 30, 2026

Management Discussion & Analysis

  • Revenue $43.3M, down 9.6% YoY from $48.0M, driven by lower pellet procedures
  • Net income $9.2M vs $4.2M net loss YoY, operating margin 5.7% vs 17.2%
  • Best line: dietary supplements revenue up $0.8M; worst: pellet procedures down $5.1M, or 15.1%
  • Cash $8.9M vs $24.1M at December 31, 2025; operating cash flow $6.4M vs $27.6M
  • Recall, clinic attrition and covenant pressure: revolver reduced to $35.0M, additional liquidity actions under evaluation

Risk Factors

  • New covenant risk: November 4, 2026 First Amendment waived noncompliance for the period ended September 30, 2026
  • Financial risk: $125.0 million variable-rate Term Loan increases exposure to rising interest expense
  • Liquidity risk: $35.0 million revolving facility and covenant breach could accelerate outstanding debt
  • Strategic flexibility risk: Credit Agreement covenants may restrict expansion, business activities, and future financing

AI summary of the BTMD 10-Q filed . Generated from the filing text; verify against the original.View on SEC EDGAR10-K vs 10-Q vs 8-K

AI 8-K Current Report Analysis

The most recent material events, by 8-K item

Filed Nov 4, 2026Full analysis →

Item 2.02: Results of Operations and Financial Condition

  • Q3 2026 financial results announced for quarter ended September 30, 2026
  • Press release contains the substantive operating and financial details, furnished as Exhibit 99.1

Item EX-99.1: Item EX-99.1

  • Q3 revenue $43.3M, down 9.6%, with procedure revenue down 15.1% to $28.9M
  • Gross margin fell to 67.7% from 71.8%, reflecting continued voluntary-recall effects and lower-margin third-party pellets
Filed Aug 5, 2026Full analysis →

Item EX-99.1: Item EX-99.1

  • Q2 revenue fell 9.5% to $44.2M, with procedure revenue down 13.9% to $30.3M from the January 2026 voluntary recall
  • Gross margin contracted to 65.4% from 71.6% due to higher replacement-product costs and reduced Asteria Health manufacturing efficiency

Item 2.02: Results of Operations and Financial Condition

  • Biote reported financial results for Q2 ended June 30, 2026
  • Press release dated August 5, 2026 contains the substantive earnings details
Filed Jun 17, 2026Full analysis →

Item 5.02: Departure/Appointment of Directors or Principal Officers

  • Interim CEO Robert Peterson receives $658,800 base salary and incentive eligibility up to 72.5% of salary
  • Stock option award equals 0.56% of outstanding shares, with an additional equal award if appointed permanent CEO

AI summaries of BTMD 8-K current reports filed with the SEC. What 8-K item codes mean

SignalX for BTMD

Don't miss the next BTMD filing

  • Alerts as it files. A push when BTMD files an 8-K or an insider trades.
  • Fund moves. Which tracked funds opened, added or cut BTMD, by share count.
  • Ask anything. An AI agent that reads every BTMD filing and answers with sources.

BTMD alerts on your phone. Follow it in the SignalX Android app.

Get it on Google Play

Recent Insider Transactions (Form 4)

Latest reported trades by officers, directors and 10% owners

InsiderTypeDatePrice
Beer Marc DBuyAug 11, 2026$1.55
Beer Marc DBuyAug 10, 2026$1.53
Peterson Robert CharlesAJun 12, 2026-
Christensen BretAJun 8, 2026-
Beer Marc DAJun 8, 2026-
Jacoby Dana LynnAMay 12, 2026-
HEYER ANDREW RAMay 12, 2026-
HEYER ANDREW RAMay 12, 2026-

Financial Summary
XBRL

Annual financial summary from SEC XBRL data
MetricFY2023FY2024FY2025
Profitability
Revenue$185.4M$197.2M$192.2M
Operating Income-$31.6M$35.6M
Net Income-$3.2M$27.0M
Op. Margin-16.0%18.5%
Net Margin-1.6%14.1%
Balance Sheet
Total Assets-$122.4M$107.6M
Equity-$29.4M-$105.9M-$58.5M
ROE--3.0%-46.2%
Per Share
EPS$0.13$0.09$0.74
Cash Flow
Operating CF$26.9M$45.2M$35.2M
CapEx-$6.4M$5.0M

Source: XBRL data in biote Corp. (BTMD)'s 10-K filings on SEC EDGAR, in USD. Compare across companies →

BTMD filing archive

AI analysis pages for each 10-K, 10-Q and 8-K

Latest 2026 SEC Filings: 10-K, 10-Q, 8-K & Form 4

FormFiling dateAnalysisSEC
10-QNov 9, 2026Analysis
8-KNov 4, 2026Analysis-
SC 13GAug 28, 2026-
4Aug 12, 2026--
10-QAug 7, 2026Analysis
8-KAug 5, 2026Analysis-
8-KJun 17, 2026Analysis-
4Jun 16, 2026--
4Jun 10, 2026-
4Jun 10, 2026-
8-KJun 2, 2026Analysis
8-KMay 18, 2026Analysis
4May 14, 2026-
4May 13, 2026-
4May 13, 2026-
4May 13, 2026-
4May 13, 2026-
10-QMay 11, 2026Analysis
8-KMay 6, 2026Analysis
4May 4, 2026--
4Apr 3, 2026--
4Apr 3, 2026--
8-KApr 3, 2026Analysis-
10-KMar 13, 2026Analysis
8-KMar 11, 2026Analysis-

Related Health Care companies

All Health Care →

BTMD SEC filings: frequently asked questions

What was BTMD's revenue in fiscal year 2025?

For the fiscal year ended December 31, 2025 (FY2025), biote Corp. (BTMD) reported revenue of $192.2 million (down 2.5% from FY2024) and net income of $27.0 million. Diluted EPS was $0.74. The figures come from the XBRL data in the 10-K.

What are the main risks in BTMD's latest 10-K?

In the 10-K filed March 13, 2026, biote Corp. (BTMD) flagged: Regulatory risk from potential liability and recalls linked to compounded drug formulations via outsourcing facilities, posing reputational harm. Macroeconomic exposure from 2.5% revenue decline to $192.2M in 2025 due to slowdown in new clinic additions and procedure volumes. (AI summary of the Risk Factors section.)

What did BTMD report in its latest 8-K?

biote Corp. (BTMD) filed an 8-K on November 4, 2026 reporting Item 2.02 (Results of Operations and Financial Condition). Q3 2026 financial results announced for quarter ended September 30, 2026.

What are the latest BTMD SEC filings?

biote Corp. (BTMD) filed its latest 10-K annual report on March 13, 2026, a 10-Q quarterly report on November 9, 2026, an 8-K current report on November 4, 2026 and a Form 4 insider filing on August 12, 2026.

What is BTMD's SEC CIK number?

biote Corp. (BTMD)'s SEC Central Index Key (CIK) is 1819253. EDGAR lists every BTMD filing under that number.

Ask anything about BTMD

The research agent reads BTMD's filings, financials, insider trades and 13F holders, then answers with sources.